457 related articles for article (PubMed ID: 19201489)
21. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
Dean B
Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
[TBL] [Abstract][Full Text] [Related]
22. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
Davie BJ; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
[TBL] [Abstract][Full Text] [Related]
23. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
[TBL] [Abstract][Full Text] [Related]
24. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC
Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
[TBL] [Abstract][Full Text] [Related]
26. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
Bolbecker AR; Shekhar A
Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
[TBL] [Abstract][Full Text] [Related]
27. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
28. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.
Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ
J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902
[TBL] [Abstract][Full Text] [Related]
29. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
Foster DJ; Conn PJ
Neuron; 2017 May; 94(3):431-446. PubMed ID: 28472649
[TBL] [Abstract][Full Text] [Related]
30. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
[TBL] [Abstract][Full Text] [Related]
32. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.
Brady AE; Jones CK; Bridges TM; Kennedy JP; Thompson AD; Heiman JU; Breininger ML; Gentry PR; Yin H; Jadhav SB; Shirey JK; Conn PJ; Lindsley CW
J Pharmacol Exp Ther; 2008 Dec; 327(3):941-53. PubMed ID: 18772318
[TBL] [Abstract][Full Text] [Related]
33. Discovery and structure-activity relationships study of positive allosteric modulators of the M
Tanaka H; Negoro K; Koike T; Tsukamoto I; Yokoyama K; Maeda J; Inagaki Y; Shimoshige Y; Ino K; Ishizu K; Takahashi T
Bioorg Med Chem; 2020 Jul; 28(13):115531. PubMed ID: 32386953
[TBL] [Abstract][Full Text] [Related]
34. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
35. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.
Shirey JK; Xiang Z; Orton D; Brady AE; Johnson KA; Williams R; Ayala JE; Rodriguez AL; Wess J; Weaver D; Niswender CM; Conn PJ
Nat Chem Biol; 2008 Jan; 4(1):42-50. PubMed ID: 18059262
[TBL] [Abstract][Full Text] [Related]
36. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
Lazareno S; Popham A; Birdsall NJ
J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
[TBL] [Abstract][Full Text] [Related]
37. Muscarinic receptors and novel strategies for the treatment of age-related brain disorders.
Ehlert FJ; Roeske WR; Yamamura HI
Life Sci; 1994; 55(25-26):2135-45. PubMed ID: 7997072
[TBL] [Abstract][Full Text] [Related]
38. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.
Mistry SN; Jörg M; Lim H; Vinh NB; Sexton PM; Capuano B; Christopoulos A; Lane JR; Scammells PJ
J Med Chem; 2016 Jan; 59(1):388-409. PubMed ID: 26624844
[TBL] [Abstract][Full Text] [Related]
39. Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.
Tarr JC; Turlington ML; Reid PR; Utley TJ; Sheffler DJ; Cho HP; Klar R; Pancani T; Klein MT; Bridges TM; Morrison RD; Blobaum AL; Xiang Z; Daniels JS; Niswender CM; Conn PJ; Wood MR; Lindsley CW
ACS Chem Neurosci; 2012 Nov; 3(11):884-95. PubMed ID: 23173069
[TBL] [Abstract][Full Text] [Related]
40. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning.
Sheffler DJ; Williams R; Bridges TM; Xiang Z; Kane AS; Byun NE; Jadhav S; Mock MM; Zheng F; Lewis LM; Jones CK; Niswender CM; Weaver CD; Lindsley CW; Conn PJ
Mol Pharmacol; 2009 Aug; 76(2):356-68. PubMed ID: 19407080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
